Showing posts with label Prescription opioid. Show all posts
Showing posts with label Prescription opioid. Show all posts

Monday, 9 May 2016

PubMed Update April 2016

23 for this month! Lots of interesting stuff, from large-scale epidemiology to randomized controlled trials.

Krieter P, Chiang N, Gyaw S, Skolnick P, Crystal R, Keegan F, Aker J, Beck M, Harris J.
J Clin Pharmacol. 2016 May 5. doi: 10.1002/jcph.759. [Epub ahead of print]
Comment: Details on the pharmacokinetics and usability studies for the new nasal device.

Madah-Amiri D, Clausen T.
Addiction. 2016 May 3. doi: 10.1111/add.13400. [Epub ahead of print] No abstract available.
Comment: Large-scale naloxone requires public health support.

Wilkerson RG, Kim HK, Windsor TA, Mareiniss DP.
Emerg Med Clin North Am. 2016 May;34(2):e1-e23. doi: 10.1016/j.emc.2015.11.002. Epub 2016 Feb 17. Review.
Comment: Focuses on risk factors for problematic opioid use and naloxone.


Kunøe N, Opheim A, Solli KK, Gaulen Z, Sharma-Haase K, Latif ZE, Tanum L.
BMC Pharmacol Toxicol. 2016 Apr 28;17(1):18. doi: 10.1186/s40360-016-0061-1.
Comment: Methods paper for above planned study.

Arelin V, Schmidt JJ, Kayser N, Kühn-Velten WN, Suhling H, Eden G, Kielstein JT.
Clin Nephrol. 2016 Apr 27. [Epub ahead of print]
Comment: Doesn’t really remove methadone, so not useful in an overdose but also not problematic for patients on methadone undergoing light-chain removal.

Madah-Amiri D, Clausen T, Lobmaier P.
Drug Alcohol Depend. 2016 Apr 14. pii: S0376-8716(16)30034-5. doi: 10.1016/j.drugalcdep.2016.04.007. [Epub ahead of print]
Comment: Title is self-explanatory.

Weiner SG, Raja AS, Bittner JC, Curtis KM, Weimersheimer P, Hasegawa K, Espinola JA, Camargo CA Jr.
Acad Emerg Med. 2016 Apr 21. doi: 10.1111/acem.12992. [Epub ahead of print]
Comment: Intriguing look at ED policies in New England. 18% had an opioid screening tool, 78% used the PDMP, 41% alerted the primary doctor when prescribing opioids, 70% gave substance use treatment referrals, and 12% offered take-home naloxone.

Pade P, Fehling P, Collins S, Martin L.
Subst Abus. 2016 Apr 19:0. [Epub ahead of print]
Comment: Naloxone in a residential treatment program. Hopefully the first bit of data with much more to come.

Takeda MY, Katzman JG, Dole E, Bennett MH, Alchbli A, Duhigg D, Yonas H.
Subst Abus. 2016 Apr 19:0. [Epub ahead of print]
Comment: New Mexico study of 164 chronic pain patients on opioids who were provided naloxone. There were no overdoses.

Friedman MS, Manini AF.
J Med Toxicol. 2016 Apr 15. [Epub ahead of print]
Comment: Fascinating abstract – I don’t have full access. They set up “naloxone criteria” of (1) respiratory rate <12, miotic pupils, or drug paraphernalia, and (2) altered mental status by AVPU or GCS and then looked to see if those criteria predicted a beneficial effect of naloxone. They did – with an OR of 7 and 83% sensitivity. Miotic pupils were the best predictor of a response to naloxone. Authors also found that naloxone was underutilized – in only 44.2% of cases where it may have been beneficial. This is a fascinating area, as we don’t yet understand the reasons why naloxone is or is not administered in emergency services.

Darke S, Duflou J.
Addiction. 2016 Apr 15. doi: 10.1111/add.13429. [Epub ahead of print]
Comment: 6-MAM, the best way to confirm heroin as a cause of overdose death, is only present if the death occurs in under 30 minutes. In this study, 6-MAM was present in 43% of heroin overdose cases, suggesting that most people took longer to expire.

Lewis DA, Park JN, Vail L, Sine M, Welsh C, Sherman SG.
Am J Public Health. 2016 Apr 14:e1-e4. [Epub ahead of print]
Comment: Distribution program increased self-efficacy.

Chronister KJ, Lintzeris N, Jackson A, Ivan M, Dietze P, Lenton S, Kearley J, van Beek I.
Drug Alcohol Rev. 2016 Apr 13. doi: 10.1111/dar.12400. [Epub ahead of print]
Comment: First data on an Australian naloxone program. 83 people given naloxone. Among the 42% completing follow-up, 30 overdoses were successfully reversed and participants still felt informed and able to use naloxone.

Hoback J.
State Legis. 2016 Apr;42(4):9-13. No abstract available.
Comment: On a quick glance, seems a bit inflammatory.

Harned M, Sloan P.
Expert Opin Drug Saf. 2016 Apr 26:1-8. [Epub ahead of print]
Comment: Prospective trials are needed to evaluate longterm opioid therapy for chronic pain.

Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Boney TY, Hoskinson RA Jr, Wilson D, McDonald R, Rotrosen J, Gourevitch MN, Gordon M, Fishman M, Chen DT, Bonnie RJ, Cornish JW, Murphy SM, O'Brien CP.
N Engl J Med. 2016 Mar 31;374(13):1232-42. doi: 10.1056/NEJMoa1505409.
Comment: Pretty good data on extended-release naltrexone and low overdose risk. Unfortunately, overdose wasn’t specifically asked about, but instead was treated as any other adverse events in a clinical trial and had to be reported by the participants.

Yablonsky TA, Thompson GL.
W V Med J. 2016 Mar-Apr;112(2):16-7. No abstract available.
Comment: Can’t access, but there are a lot.

Hein H, Püschel K, Schaper A, Iwersen-Bergmann S.
Arch Kriminol. 2016 Jan-Feb;237(1-2):38-46. German.
Comment: Lockboxes.

Asplund J.
Hosp Health Netw. 2016 Jan;90(1):20, 22, 2.
Comment: This is apparently about police and naloxone.

Rudd RA, Aleshire N, Zibbell JE, Gladden RM.
MMWR Morb Mortal Wkly Rep. 2016 Jan 1;64(50-51):1378-82. doi: 10.15585/mmwr.mm6450a3.
Comment: Really well done. Discusses opioids in a sophisticated and honest manner. Impressive work from the CDC.

Larochelle MR, Liebschutz JM, Zhang F, Ross-Degnan D, Wharam JF.
Ann Intern Med. 2016 Jan 5;164(1):1-9. doi: 10.7326/M15-0038. Epub 2015 Dec 29.
Comment: Patients who have an overdose usually continue to receive opioids. If opioids stop, they have a lower risk of recurrent overdose.

Sgarlato A, deRoux SJ.
Forensic Sci Med Pathol. 2015 Sep;11(3):388-94. doi: 10.1007/s12024-015-9699-z. Epub 2015 Aug 2.
Comment: 36.7% of decedents had a valid opioid prescription; benzos were involved in 68.4% of cases with alprazolam the most common (35.1%).

Darke S, Slade T, Ross J, Marel C, Mills KL, Tessson M.
Addict Behav. 2015 Nov;50:78-83. doi: 10.1016/j.addbeh.2015.06.030. Epub 2015 Jun 14.
Comment: Heavy drinking was associated with overdose (OR 1.6).

Wednesday, 20 April 2016

PubMed Update March 2016

23 this month.

McDonald R, Strang J.
Addiction. 2016 Mar 30. doi: 10.1111/add.13326. [Epub ahead of print] Review.
Comments: Take-home naloxone meets all Bradford Hill criteria for causality in reducing opioid overdose mortality. Incidence of fatality among overdoses in the setting of take-home naloxone was 0.8%.

Loreck D, Brandt NJ, DiPaula B.
J Gerontol Nurs. 2016 Apr 1;42(4):10-5. doi: 10.3928/00989134-20160314-04.
Comments: A review of the U.S. situation and treatments for opioid use disorder.

Darke S, Marel C, Mills KL, Ross J, Slade T, Tessson M.
Drug Alcohol Depend. 2016 May 1;162:206-10. doi: 10.1016/j.drugalcdep.2016.03.010. Epub 2016 Mar 18.
Comments: Heroin use is associated with 25-50 years of life lost. Over half of deaths and nearly two-thirds of years of life lost were due to opioid overdose.

Olsson MO, Bradvik L, Öjehagen A, Hakansson A.
Drug Alcohol Depend. 2016 May 1;162:176-81. doi: 10.1016/j.drugalcdep.2016.03.009. Epub 2016 Mar 17.
Comments: Accidental overdose death and suicide are distinct entities, with distinct predictive variables. This is important.

Saucier CD, Zaller N, Macmadu A, Green TC.
Drug Alcohol Depend. 2016 May 1;162:211-8. doi: 10.1016/j.drugalcdep.2016.03.011. Epub 2016 Mar 19.
Comments: Harm reduction programs training law enforcement, a critical step forward.

Levine M, Sanko S, Eckstein M.
Prehosp Emerg Care. 2016 Mar 28:1-4. [Epub ahead of print]
Comments: Studies of pre-hospital naloxone without transport to the hospital have uniformly shown extremely low rates of re-overdose or death in the ensuing 24 hours. This study examined 205 people over a much longer period and identified 3 deaths in the subsequent month. Again, this supports the relative safety of naloxone management and yet emphasizes the high risk of mortality in this population.

Lott DC, Rhodes J.
Am J Addict. 2016 Apr;25(3):221-6. doi: 10.1111/ajad.12364. Epub 2016 Mar 22.
Comments: Education is excellent, but providing the medication on-site is critical.

Kitch BB, Portela RC.
Prehosp Emerg Care. 2016 Mar-Apr;20(2):226-9. doi: 10.3109/10903127.2015.1076097.
Comments: Police administering naloxone in the setting of fentanyl overdoses.

Burns G, DeRienz RT, Baker DD, Casavant M, Spiller HA.
Clin Toxicol (Phila). 2016 Mar 21:1-4. [Epub ahead of print]
Comments: Fascinating article! Many of us have wondered why fentanyl is such an extreme problem when used illicitly. This paper describes the phenomenon of chest wall rigidity with rapid IV administration of fentanyl, a possible explanation for the high risk of death in the setting of increased illicit fentanyl availability.

Riley ED, Evans JL, Hahn JA, Briceno A, Davidson PJ, Lum PJ, Page K.
Am J Public Health. 2016 May;106(5):915-7. doi: 10.2105/AJPH.2016.303084. Epub 2016 Mar 17.
Comments: Increased use is associated with increased overdose. This has been a persistent finding, potentially in conflict with the findings that periods of abstinence are associated with overdose. That is to say, even though low tolerance is a risk for overdose, it seems that more regular rather than more sporadic use increases overdose risk. Prevention messaging on this topic remains challenging.

Frieden TR, Houry D.
N Engl J Med. 2016 Mar 15. [Epub ahead of print]
Comments: An editorial on the new CDC guidelines described below.

Dowell D, Haegerich TM, Chou R.
JAMA. 2016 Mar 15. doi: 10.1001/jama.2016.1464. [Epub ahead of print]
Comments: New guidelines for opioid prescribing that emphasize reliance upon other therapies first and limited doses of opioids. They do recommend use of opioid agonist treatments for patients with co-morbid chronic pain and opioid use disorder, such as buprenorphine which can be prescribed by general practitioners in the U.S., and co-prescription of naloxone to patients on higher doses (>50 morphine equivalent milligrams) or other risk factors.

McAuley A, Munro A, Bird SM, Hutchinson SJ, Goldberg DJ, Taylor A.
Drug Alcohol Depend. 2016 May 1;162:236-40. doi: 10.1016/j.drugalcdep.2016.02.031. Epub 2016 Mar 3.
Comments: Increased utilization but reduced likelihood of participants actually carrying naloxone on their person.

Dion KA.
J Addict Nurs. 2016 Jan-Mar;27(1):7-11. doi: 10.1097/JAN.0000000000000106.
Comments: Training nursing students in opioid overdose management.

Nielsen S, Van Hout MC.
Int J Drug Policy. 2016 Feb 15. pii: S0955-3959(16)30014-7. doi: 10.1016/j.drugpo.2016.02.006. [Epub ahead of print]
Comments: There’s some information out there but much more needed.


The next series of articles are all related to the lead author's (Dr Strang) belief that nasal naloxone is problematic; the final 5 being responses to the lead author’s recent article in Addiction critiquing nasal naloxone. Dr Strang has been a longtime advocate of naloxone, but not nasally administered. It’s important to note, as can be seen in the disclosures of his papers, that he/his employer hold a patent for buccal naloxone which is promoted in at least two of the papers (#17 & 18). I’ll withhold any further comments.

Strang J, McDonald R, Alqurshi A, Royall P, Taylor D, Forbes B.
Drug Alcohol Depend. 2016 Mar 9. pii: S0376-8716(16)00141-1. doi: 10.1016/j.drugalcdep.2016.02.042. [Epub ahead of print] Review.

Alqurshi A, Kumar Z, McDonald R, Strang J, Buanz A, Ahmed S, Allen E, Cameron P, Rickard JA, Sandhu V, Holt C, Stansfield R, Taylor D, Forbes B, Royall PG.
Mol Pharm. 2016 Mar 28. [Epub ahead of print]

Strang J, Mcdonald R.
Addiction. 2016 Apr;111(4):590-2. doi: 10.1111/add.13319. No abstract available.

Balster RL, Walsh SL.
Addiction. 2016 Apr;111(4):589-90. doi: 10.1111/add.13274. No abstract available.

Dale O.
Addiction. 2016 Apr;111(4):587-9. doi: 10.1111/add.13267. No abstract available.

Lobmaier PP, Clausen T.
Addiction. 2016 Apr;111(4):586-7. doi: 10.1111/add.13261. No abstract available.

Dietze P, Cantwell K.
Addiction. 2016 Apr;111(4):584-6. doi: 10.1111/add.13260. No abstract available.

Winstanley EL.
Addiction. 2016 Apr;111(4):583-4. doi: 10.1111/add.13255. No abstract available.


Tuesday, 22 March 2016

PubMed Update February 2016

Ten articles for February 2016.

[No authors listed]
ED Manag. 2016 Feb;28(2):13-9.
Comments: Review of the new CDC opioid prescribing guidelines.

Lenton SR, Dietze PM, Jauncey M.
Med J Aust. 2016 Mar 7;204(4):146-7. No abstract available.
Comments: Naloxone can now be over the counter in Australia, but there’s some work to be done in product design.

King R.
NASN Sch Nurse. 2016 Mar;31(2):96-101. doi: 10.1177/1942602X16628890.
Comments: Naloxone for school nurses in Delaware.

Agahi M, Shakoori V, Marashi SM.
Sultan Qaboos Univ Med J. 2016 Feb;16(1):e113-4. doi: 10.18295/squmj.2016.16.01.022. Epub 2016 Feb 2. No abstract available.
Comments: Long QT interval is a side effect of high methadone doses.


Ahlner J, Holmgren A, Jones AW.
Forensic Sci Int. 2016 Feb 3;265:138-143. doi: 10.1016/j.forsciint.2016.01.036. [Epub ahead of print]
Comments: Yet another population that may benefit from overdose prevention programming – persons arrested for impaired driving.

Jones CM, Lurie PG, Compton WM.
Am J Public Health. 2016 Apr;106(4):689-90. doi: 10.2105/AJPH.2016.303062. Epub 2016 Feb 18.
Comments: Some increase in sales; much of this increase may be accounted for by a selected number of programs. These data were also presented at the FDA meeting on naloxone in July 2015.


Butler MM, Ancona RM, Beauchamp GA, Yamin CK, Winstanley EL, Hart KW, Ruffner AH, Ryan SW, Ryan RJ, Lindsell CJ, Lyons MS.
Ann Emerg Med. 2016 Feb 10. pii: S0196-0644(15)01567-X. doi: 10.1016/j.annemergmed.2015.11.033. [Epub ahead of print]
Comments: 59% of opioid dependent participants were initially exposed via a medical prescription to them and 29% of those prescriptions came from emergency departments.

McLean K.
Int J Drug Policy. 2016 Mar;29:19-26. doi: 10.1016/j.drugpo.2016.01.009. Epub 2016 Jan 18.
Comments: This is fascinating. Poverty and social isolation.

Paulozzi LJ, Zhou C, Jones CM, Xu L, Florence CS.
Pharmacoepidemiol Drug Saf. 2016 Feb 10. doi: 10.1002/pds.3980. [Epub ahead of print]
Comments: Studying opioid prescribing is really complicated, because it involves making sense of – and trying to quantify – very complex and confusing medical decisions. This is an interesting analysis attempting to determine how much documentation of concerning opioid use behaviors results in changes in opioid prescribing.

Haug NA, Bielenberg J, Linder SH, Lembke A.
Subst Abus. 2016 Jan-Mar;37(1):35-41. doi: 10.1080/08897077.2015.1129390.

Comments: Naloxone-trained individuals on Twitter “had the highest optimism and the lowest amount of burnout and stigma.” 

Wednesday, 12 August 2015

PubMed Update June - July 2015

Great stuff this time! 34 in two months.


Wheeler E, Jones TS, Gilbert MK, Davidson PJ.
MMWR Morb Mortal Wkly Rep. 2015 Jun 19;64(23):631-5.
Comment: The long-awaited sequel to 2010’s blockbuster naloxone MMWR report! 152,283 laypersons trained and 26,463 overdose reversals reported to naloxone programs through 2014.

Mars SG, Fessel JN, Bourgois P, Montero F, Karandinos G, Ciccarone D.
Soc Sci Med. 2015 Jun 30;140:44-53. doi: 10.1016/j.socscimed.2015.06.032. [Epub ahead of print]
Comment: Interesting use of qualitative data exploring the role of heroin markets on overdose risk, suggesting that factors such as open-air versus behind-closed-door markets can affect risk.

Cropsey KL, Stevens EN, Valera P, Brendan Clark C, Bulls HW, Nair P, Lane PS.
Drug Alcohol Depend. 2015 Jul 10. pii: S0376-8716(15)00352-X. doi: 10.1016/j.drugalcdep.2015.06.038. [Epub ahead of print]
Comment: There’s a movement toward not prescribing opioids with benzodiazepines at all. This makes some sense from an overdose prevention perspective, however the impact of such a policy is unknown. Those who require both opioids and benzodiazepines generally have far more complex and substantial mental health challenges. Just removing one or the other of the agents may results in worsening mental health or even increased rates of self-harm. Or not. Nobody knows.

Soukup-Baljak Y, Greer AM, Amlani A, Sampson O, Buxton JA.
Int J Drug Policy. 2015 Jul 2. pii: S0955-3959(15)00200-5. doi: 10.1016/j.drugpo.2015.06.006. [Epub ahead of print]
Comment: This is interesting, particularly in an era of frequent high-potency batches of heroin or even pure fentanyl derivatives. Subjects recommend using words like “dangerous” or “lethal” instead of “potent” which can be misconstrued as desirable. They also emphasized timeliness. As one of the first studies to really look at this issue, this paper is well worth the read.

Visconti AJ, Santos GM, Lemos NP, Burke C, Coffin PO.
J Urban Health. 2015 Jun 16. [Epub ahead of print]
Comment: Epidemiology of opioid overdose mortality in San Francisco – the first since Pete Davidson’s seminal geocoding paper in 2003 that led SF to refocus overdose prevention efforts to the hardest hit neighborhoods. This paper documents that heroin overdose is now remarkably rare in San Francisco, although for me it raises more questions than it answers.


Hill R, Lyndon A, Withey S, Roberts J, Kershaw Y, MacLachlan J, Lingford-Hughes A, Kelly E, Bailey C, Hickman M, Henderson G.
Neuropsychopharmacology. 2015 Jul 14. doi: 10.1038/npp.2015.201. [Epub ahead of print]
Comment: Okay, this is a very cool mouse study. They gave morphine to mice until they developed tolerance. The tolerance to respiratory depression effects of morphine were reversed by ethanol. Methadone and buprenorphine seemed to protect mice from this reversal of tolerance effect. Very cool. This is why I do these reviews.

Binswanger IA, Koester S, Mueller SR, Gardner EM, Goddard K, Glanz JM.
J Gen Intern Med. 2015 Jun 9. [Epub ahead of print]
Comment: Interesting initial look at prescriber concerns regarding prescribing naloxone from primary care practices. Issues are knowledge about lay use, uncertainty about who to prescribe to, logistical barriers, fears about offending patients, fears about risky use, and discomfort with their own opioid prescribing practices.

Rando J, Szari S, Kumar G, Lingadevaru H.
Am J Emerg Med. 2015 Jun 18. pii: S0735-6757(15)00509-4. doi: 10.1016/j.ajem.2015.06.032. [Epub ahead of print] No abstract available.
Comment: A very sad case in which a 14 year old boy accessed his mother’s methadone (apparently prescribed for pain) and had severe disease of the cerebellum as a result. When we speak of opioid overdose, we are generally talking about respiratory depression, but there are some complications that can be unique to particular opioids.

Jones CM, Logan J, Gladden RM, Bohm MK.
MMWR Morb Mortal Wkly Rep. 2015 Jul 10;64(26):719-25.
Comment: Just after 2010 there was a big uptick in heroin use and overdose mortality. Again, this suggests that the increases in heroin use and sequelae were not simply the inevitable consequence of increased opioid dependence, but resulted from – or were substantially contributed to by – restrictions on prescription opioids. It is essential to recognize this in order to minimize the harms of the new/emerging paradigm of opioid prescribing.

Barocas JA, Baker L, Hull SJ, Stokes S, Westergaard RP.
Drug Alcohol Depend. 2015 Jun 24. pii: S0376-8716(15)00322-1. doi: 10.1016/j.drugalcdep.2015.06.023. [Epub ahead of print]
Comment: People who have been incarcerated are more likely to access naloxone programs. This is consistent with the aims of naloxone programming.

Bachhuber MA, McGinty EE, Kennedy-Hendricks A, Niederdeppe J, Barry CL.
PLoS One. 2015 Jul 1;10(7):e0130050. doi: 10.1371/journal.pone.0130050. eCollection 2015.
Comment: Useful study testing different approaches to providing information about naloxone programming. The finding that adding sympathetic narratives to factual information roughly doubles support for the programs is consistent with recent experience in which personal exposure to the tragedy of opioid overdose has led many people in positions of power to advocate for naloxone programming.

Betts KS, McIlwraith F, Dietze P, Whittaker E, Burns L, Cogger S, Alati R.
Drug Alcohol Depend. 2015 Jun 22. pii: S0376-8716(15)00319-1. doi: 10.1016/j.drugalcdep.2015.06.020. [Epub ahead of print]
Comment: This is fascinating. Polysubstance use research is an underdeveloped (and surprisingly challenging) avenue of research. The finding that those with less psychological distress are protected by a combination of agonist maintenance and prescription drug use is of particular interest…

McLaughlin PJ, Zagon IS.
Biochem Pharmacol. 2015 Jun 25. pii: S0006-2952(15)00332-9. doi: 10.1016/j.bcp.2015.06.016. [Epub ahead of print]
Comment: This isn’t really about overdose or even substance use, but it’s about naloxone and naltrexone – opioid blockers – and it’s intriguing. There are some other potential therapeutic roles for opioid blockade, related to complications of diabetes, autoimmune disorders, and cancer.

Bertaso A, Musile G, Gottardo R, Seri C, Tagliaro F.
J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Jul 19;1000:130-135. doi: 10.1016/j.jchromb.2015.07.024.
Comment: Methorphan, a codeine analog and related to dextromethorphan, is being added to heroin sometimes. This paper describes how to test for it.

Neale J, Strang J.
Addiction. 2015 Jun 27. doi: 10.1111/add.13027. [Epub ahead of print]
Comment: Medical professionals are generally cautious in administering naloxone these days because we know it makes patients miserable. Low doses and, if in a monitored setting, only using it when oxygen saturation begins to decline helps to minimize the untoward effects. In this study naloxone had a bad rap but respondents often didn’t know that it had been administered because it was done cautiously.

Dolgin E.
Nature. 2015 Jun 25;522(7557):S60-1. doi: 10.1038/522S60a. No abstract available.
Comment: There’s a serious problem with the term “abuse-deterrent formulations.” These are formulations of opioids that are more difficult to inject - or in some cases insufflate. They should really be referred to as “injection-deterrent formulations.” They don’t prevent somebody from developing an opioid habit. This article instead reads more like a press release for “abuse-deterrent formulations.”

Winter RJ, Stoové M, Degenhardt L, Hellard ME, Spelman T, Jenkinson R, McCarthy DR, Kinner SA.
Drug Alcohol Depend. 2015 Aug 1;153:43-9. doi: 10.1016/j.drugalcdep.2015.06.011. Epub 2015 Jun 16.
Comment: People overdose after they leave prison.

Knudsen HK.
J Stud Alcohol Drugs. 2015 Jul;76(4):644-54.
Comment: The average U.S. state has 8 physicians per 100,000 residents able to prescribe buprenorphine for opioid dependence. This rate is even worse in many states, from a low of 1.9 in Nebraska to a high of 27.9 in Vermont. Appalachia – probably the region with the most urgent need – has a rate of 3 to 11 / 100,000 residents. We really need to do something about this waiver situation.

Mitra G, Wood E, Nguyen P, Kerr T, DeBeck K.
Drug Alcohol Depend. 2015 Aug 1;153:135-9. doi: 10.1016/j.drugalcdep.2015.05.035. Epub 2015 May 28.
Comment: This is a sample of street-involved youth – 17.1% injected heroin. Any opioid use was associated with overdose, but interestingly prescription opioid use was a stronger predictor than heroin. That’s surprising. The relatively low overall rate of overdose – 7.67/100,000 person years is not surprising given the distribution of substance use.

Kanouse AB, Compton P.
J Pain Palliat Care Pharmacother. 2015 Jun;29(2):102-14. doi: 10.3109/15360288.2015.1037521.
Comment: This leaves some holes in the story, such as the role of reduced access to prescription opioids has had in rising heroin use. Another issue is the suggestion in the text that police getting naloxone has led to 10,000 lay reversals. These were lay person – aka drug user – reversals. It’s frustrating to see this misinformation being spread in the literature.

Wagner KD, Liu L, Davidson PJ, Cuevas-Mota J, Armenta RF, Garfein RS.
Drug Alcohol Depend. 2015 Aug 1;153:215-20. doi: 10.1016/j.drugalcdep.2015.05.026. Epub 2015 May 27.
Comment: Criminal justice and hospital-related opportunities for naloxone distribution.

Stancliff S, Phillips BW, Maghsoudi N, Joseph H.
J Addict Dis. 2015 Jun 16:0. [Epub ahead of print]
Comment: Excellent harm reduction review.

Rando J, Broering D, Olson JE, Marco C, Evans SB.
Am J Emerg Med. 2015 May 29. pii: S0735-6757(15)00443-X. doi: 10.1016/j.ajem.2015.05.022. [Epub ahead of print]
Comment: Naloxone should be in the hands of first responders. Even more important, however, is that naloxone is in the hands of people who use drugs – who are much more likely to be present at the time of an overdose. If the data from this paper are scientific evidence that naloxone given to first responders is associated with reduced mortality, then we had much stronger evidence for giving it to drug users in the late 20th century. Neither of those statements is true.

Schwartz RP, Kelly SM, Gryczynski J, Mitchell SG, O'Grady KE, Jaffe JH.
J Addict Dis. 2015 Jun 16:0. [Epub ahead of print]
Comment: Interesting data and experience out of Baltimore with harm reduction interventions.

Davis CS, Carr D, Southwell JK, Beletsky L.
Am J Public Health. 2015 Aug;105(8):1530-7. doi: 10.2105/AJPH.2015.302638. Epub 2015 Jun 11.
Comment: Review of police and naloxone administration.

Lindstrom HA, Clemency BM, Snyder R, Consiglio JD, May PR, Moscati RM.
Prehosp Disaster Med. 2015 Jun 10:1-5. [Epub ahead of print]
Comment: Interesting paper. Pre-hospital naloxone administrations are more likely for heroin overdose than prescription opioid overdose.

Swenson O.
Del Med J. 2015 May;87(5):147-9.
Comment: Keep your eyes out for pinpoint pupils.

Lubana SS, Genin DI, Singh N, De La Cruz A.
Am J Case Rep. 2015 Jun 8;16:353-6. doi: 10.12659/AJCR.893880.
Comment: Survival after cardiac arrest in opioid overdose is thought to be quite uncommon.

Weiss RC, Bazalo GR, Thomson H, Edwards E.
Manag Care. 2015 Feb;24(2):41-8.
Comment: This model attempts to estimate the cost to payers of the naloxone autoinjector, accounting for anticipated savings. There are some serious issues with this model that are quite disappointing. As a minor example, authors used “80%” as the likelihood naloxone would be administered. This assumption was based on a qualitative paper estimating the likelihood that naloxone would be administered if a heroin user was carrying it. In this paper it was used as the likelihood that the autoinjector would be used in an overdose if it had been prescribed. For a model such as this, that’s a quite different parameter.

Spaulding AC, Sharma A, Messina LC, Zlotorzynska M, Miller L, Binswanger IA.
Am J Public Health. 2015 May;105(5):e51-7. doi: 10.2105/AJPH.2014.302546. Epub 2015 Mar 19.
Comment: Another paper from the analysis of mortality among prisoners in the state of Georgia (not the country). Overdose was only a minor contributor, in contrast to many other prison releasee studies.

Spencer S.
Am J Nurs. 2015 Jan;115(1):13. doi: 10.1097/01.NAJ.0000459609.86788.ac. No abstract available.
Comment: Letter I’m unable to access.

Traul KA, Romero JB, Brayton C, DeTolla L, Forbes-McBean N, Halquist MS, Karnes HT, Sarabia-Estrada R, Tomlinson MJ, Tyler BM, Ye X, Zadnik P, Guarnieri M.
Lab Anim. 2015 Apr;49(2):100-10. doi: 10.1177/0023677214554216. Epub 2014 Oct 10.
Comment: Mice can handle remarkably high doses of buprenorphine without adverse effects.

Blanch B, Pearson SA, Haber PS.
Br J Clin Pharmacol. 2014 Nov;78(5):1159-66. doi: 10.1111/bcp.12446. Review.
Comment: Review of opioid use and death rates in Australia, illustrating something that looks like a very mild version of what’s happened in the U.S.

Gjersing L, Bretteville-Jensen AL.
BMC Public Health. 2014 May 10;14:440. doi: 10.1186/1471-2458-14-440.
Comment: Study in Norway of mortality among injectors recruited in 1997 and followed for 13 years, comparing men to women. Overdose was the leading cause of death. Men had a higher mortality rate but women had higher early mortality.